Panel discussion: biomarker bioanalysis in oncology drug development and personalized medicine
Watch our expert panel as they discuss the role of biomarkers in oncology drug development and personalized medicine!
The manner in which cancer grows and develops differs between individuals, meaning that patients may respond differently to the same therapeutic, affecting patient outcomes to treatment. Personalization of the therapeutic i.e. via dosage, maximizes drug efficacy and reduces the likelihood of administering a therapeutic that will produce little to no improvement in the patient.
Well-validated oncology biomarkers are critical for detecting cancers, monitoring the effect of a therapeutic and producing targeted drugs. Conducting biomarker assays in parallel to clinical trials is one method of personalizing treatment for cancer and accelerates the production of successful therapeutics.
In this Spotlight Panel discussion, our team of experts discuss the use of biomarkers currently to support oncology drug development, the challenges of implementing precision medicine practices into oncology and how platforms may progress to alleviate current bottlenecks. This conversation is guided by survey data collected throughout the Spotlight and is available here. Our experts supplement these findings with their own opinions, answer your questions in a live Q&A session and even discuss the results of live polls. Join the discussion today!
What will you learn?
- Learn about the biomarkers currently being used to support oncology drug development
- Better understand the platforms currently being utilized and the areas where these technologies could be improved
- Review the benefits and challenges of current biomarker assays and what needs to be considered when implementing these for precision oncology applications
- Consider how biomarker assays may evolve in the next 5-10 years’ time
Who may this interest?
- Laboratory managers
- Contract research organizations
- Biomarker scientists
- Precision oncology researchers
Speakers
Jialu Liu
Associate Director and Subject Matter Expert for Biomarker Services
Frontage Laboratories (PA, USA)
Dr. Jialu Liu is an Associate Director and Subject Matter Expert for the Biomarker Services team at Frontage Laboratories, providing scientific leadership and contributing to the development of the Global Biomarker Strategy. He works as a liaison between business operations, development and various other departments, and has been involved with communicating and presenting biomarker bioanalysis capabilities to biopharma sponsors. He also leads the biomarker method development team for new LBA method development, transfer and validation projects at Frontage.
Naveen Dakappagari
Head of Biomarker and Diagnostic Development
Navigate BioPharma Services, Inc., A Novartis Subsidiary (CA, USA)
Naveen is a cancer immunologist focused on guiding a team of talented scientists developing patient-centric biomarker assays and has supported the approval of the first CAR-T Therapy. Over the past 25 years, Naveen played critical roles in drug and regulated biomarker development and authored multiple best practice papers on behalf of AAPS and WRIB.
Mike Baratta
Sr. Director & Head of the Clinical Bioanalysis MS group, Preclinical Translational Science
Takeda Pharmaceuticals (MA, USA)
Mike Baratta currently serves as a Sr. Director and Head of the Clinical Bioanalysis Mass Spectrometry group for the Preclinical Translational Science function at Takeda Pharmaceuticals. He received his B.S. in Chemistry from Loyola University of Chicago (IL, USA) and a Masters Certificate in Applied Healthcare Project Management from Villanova University (PA, USA).
Mike began his career as a member of the Global Drug Metabolism group at Pharmacia/G.D. Searle (NJ, USA), transitioning to a Principal Scientist role with Pfizer (NY, USA) post-merger. Prior to joining Takeda in 2013, Mike served as Director of Nonclinical Development, Pharmacokinetics and Biometrics with Duck Flats Pharma (NJ, USA) and as a Project Manager at Advion Bioanalytical Services (NY, USA). He currently sits on several consortia for the Foundation for the National Institutes of Health, industry committees and serves as an NIH/NINDS grant reviewer. Mike is a champion for patient-centric sampling and his current research focus centers around the use of mass spectrometry to characterize PK/biomarkers to facilitate patient characterization goals.
This webinar was recorded on Monday 18th of September 2023.
In association with
